Wanbury Limited
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research
What Wanbury files
- Others58
- Updates34
- Board Meeting18
- Important7
- PPTs5
- Insider Trade5
Wanbury secured EDQM approval for Rivaroxaban API, boosting EU market access. The company also received USFDA DMF clearances for Paraxetine HCl and Metformin HCl, strengthening its product pipeline and reach for customers.
Wanbury reported Q1 FY27 PAT fell 76% to Rs 3.2 Cr, hit by surging raw material costs and logistics issues. Management anticipates Q2 recovery via cost pass-throughs, reduced finance costs from debt refinancing (<10%), and new API scale-up. Multiple regulatory approvals strengthen future growth prospects.
Wanbury received USFDA full compliance for its Metformin HCl API for multiple drug formulations, signaling strong US market potential. The company is also expanding its API business to South Korea with a new product filing.
Wanbury's Tanuku facility received a Form 483 with six observations following a USFDA inspection. The company will address these and anticipates no material impact on manufacturing operations, exports, or financial performance.
Wanbury's Tanuku facility received a USFDA Form 483 with six observations after an inspection. The company plans to address these findings. Investors should monitor this development for potential business implications.